

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.
樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

**VOLUNTARY ANNOUNCEMENT IN RELATION TO THE
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

This is a voluntary announcement made by Lepu Biopharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”).

References are made to the notice of the 2022 annual general meeting (the “**AGM**”) of the Company, the notice of the 2023 first class meeting of H Shareholders (the “**H Shareholders Class Meeting**”) of the Company and the notice of the 2023 first class meeting of Domestic Shareholders (the “**Domestic Shareholders Class Meeting**”) dated May 24, 2023 (the “**Notices**”), the circular of the AGM, the H Shareholders Class Meeting and the Domestic Shareholders Class Meeting dated May 24, 2023 (the “**Circular**”), and the announcement of the poll results of the AGM, the H Shareholders Class Meeting and the Domestic Shareholders Class Meeting dated June 15, 2023 (the “**Announcement**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Notices, the Circular and the Announcement.

As disclosed in the Announcement, the proposed amendments to the Articles in respect of the Trial Measures (the “**Proposed Amendments**”) were duly passed by the Shareholders, the Domestic Shareholders, and the H Shareholders respectively, but are subject to the draft amendments to the Listing Rules in Appendix II to the consultation paper “Rule Amendments Following Mainland China Regulation Updates and Other Proposed Rule Amendments Relating to the PRC Issuers” (the “**Draft Amendments**”) published on February 24, 2023 by the Stock Exchange, taking effect. As the Draft Amendments have taken effect on August 1, 2023, the Proposed Amendments have taken effect on August 1, 2023. Accordingly, the revised Articles of Association have also taken effect on August 1, 2023.

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC
August 1, 2023

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (Chairman), Dr. Sui Ziyue (Chief Executive Officer) and Dr. Hu Chaohong (Co-Chief Executive Officer) as executive Directors; Mr. Lin Xianghong, Mr. Yang Hongbing and Ms. Pu Jue, as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.